Lean Stack

• The bundle pairs Tirzepatide 40 (dual GIP/GLP-1 receptor agonist, 40 mg click pen) with NAD+ 1000 (1,000 mg, 3 mL cellular-energy pen) at a stated 15% saving versus separate purchase, as of 30 August 2026.
• No stack-specific trial data combining the two pens exists on Veyvora’s pages; component-level evidence applies only to each compound under its own study conditions.
• Both pens are supplied for in-vitro laboratory research use only and are not medicines, food supplements, or approved for human or veterinary administration.
• GBP unit pricing, shipping charges, and real-time stock status must be confirmed at the product detail or checkout stage.

The Lean Stack Research Bundle contains two pens: Tirzepatide 40, a dual GIP/GLP-1 receptor agonist in a 40 mg click pen, and the NAD+ 1000 research pen, a 1,000 mg, 3 mL cellular-energy pen [2][3]. Both are supplied for in-vitro laboratory research use only.

GBP unit prices for each pen are not exposed on the category page and must be confirmed at the product detail or checkout stage [2][3]. Per-click dosing specifications for each pen, including whether the 133 micrograms-per-click, 300-click specification applies to both components, require confirmation with the operator before ordering.

Individual-compound evidence exists for Tirzepatide 40 and NAD+ 1000 separately; no stack-specific trial data combining the two pens appears on Veyvora’s pages [2][3]. Researchers comparing receptor coverage across compounds may find the retatrutide versus tirzepatide comparison useful before finalising a bundle selection. For post-purchase handling, storage and stability guidance covers the conditions applicable to this pen format.

Every pen in the Lean Stack Research Bundle ships with a batch-specific certificate of analysis (CoA) tied to its batch number, covering compound identity and HPLC purity [3]. Veyvora states that each pen in the Metabolic & Weight range undergoes independent assay before dispatch, a step that directly addresses the underdosed and mislabelled product risk recognised as a problem in the research-peptide market, because assay results are tied to the specific batch rather than a generic product specification [3]. Researchers can verify a batch CoA against their pen before first use to confirm the batch number matches the supplied documentation.

For a precise account of what HPLC purity data demonstrates and where its evidential limits lie, see what HPLC purity does and does not prove rather than treating a purity figure as a complete quality assessment [3].

No cold-chain handling language, including temperature bands, insulated packaging specifications, or storage procedures referenced to ICH (International Council for Harmonisation) or WHO (World Health Organisation) guidelines, appears in the sampled Veyvora pages as of 30 August 2026 [3]. Any specific shipping-temperature or storage-condition claims for the Lean Stack bundle remain [unverified] and should be confirmed directly from the product detail or dispatch documentation before purchase.

Every pen in the Lean Stack Research Bundle, Tirzepatide 40 and NAD+ 1000, is supplied strictly for in-vitro laboratory research use and is not a medicine, not a food supplement, and not approved for human or veterinary administration [3]. Veyvora’s Metabolic & Weight category states this restriction explicitly across the entire range, and the Metabolic Reset stack page reiterates that each pen is “supplied for laboratory research use only, not for human or veterinary use” [2][3].

Veyvora offers no dosing guidance, clinical protocols, or treatment outcomes. None should be inferred from mechanistic descriptions or receptor-agonist framing on the product pages, because receptor-target language describes biochemical mechanism rather than therapeutic application [2][3]. Under MHRA (Medicines and Healthcare products Regulatory Agency) regulations, unlicensed reference peptides must not be marketed for human administration; Veyvora’s research-use language aligns with that requirement, though independent regulatory confirmation of any specific product’s status remains [unverified] [3].

Qualified researchers bear full responsibility for designing and conducting in-vitro protocols using these materials. The batch-specific CoA supplied with each pen confirms compound identity and HPLC purity for research verification purposes only and does not constitute a safety or suitability assessment for any biological system [2][3].

Researchers evaluating mitochondrial peptides such as MOTS-C and SS-31 outside the Lean Stack scope can consult the MOTS-c versus SS-31 comparison for mechanism-level differentiation. To review the full range of available research compounds, including Retatrutide 40, Tesamorelin 20, and others in the Metabolic & Weight category, visit Veyvora’s research-peptide catalogue and confirm current pricing, stock status, and batch availability directly on the product detail page before placing an order.